In 2013, Hagens Berman filed a class action case alleging that the 2005 settlement of a patent infringement lawsuit between Kos Pharmaceuticals and Barr Laboratories was a “pay-for-delay” agreement that effectively blocked all generic versions of the cholesterol drug Niaspan from entering the U.S. market until 2013 – forcing purchasers to pay monopoly prices for years longer than they should have. The suit alleges that the settlement was anticompetitive and caused purchasers of Niaspan to incur substantial damages. Kos, which is now part of AbbVie, and Barr, which is now part of Teva, both deny the allegations, claiming that the settlement was entirely legal.
The litigation captioned In re Niaspan Antitrust Litigation (Civil Action No. 2:13-md-2460) is pending in the U.S. District Court for the Eastern District of Pennsylvania before the Honorable Jan E. DuBois.
On September 8, 2014, Judge DuBois rejected the defendants’ motion to dismiss the consolidated complaints of a proposed class of direct-purchaser plaintiffs, for which Hagens Berman has been appointed co-lead counsel. Fact discovery closed on March 30, 2018, and the parties are now engaged in expert discovery. Plaintiffs’ motion to certify the class of direct purchasers will be filed in December 2018.
Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.